H Joensuu

Summary

Affiliation: Helsinki University Central Hospital
Country: Finland

Publications

  1. ncbi request reprint Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer
    Heikki Joensuu
    Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland
    N Engl J Med 354:809-20. 2006
  2. ncbi request reprint Lymphatic vessel density in vocal cord carcinomas assessed with LYVE-1 receptor expression
    Walter J Koskinen
    Department of Virology, Haartman Institute, University of Helsinki, Finland
    Radiother Oncol 77:172-5. 2005
  3. pmc Expression of KIT receptor tyrosine kinase in endothelial cells of juvenile brain tumors
    Marjut Puputti
    Helsinki Biomedical Graduate School, Helsinki, Finland
    Brain Pathol 20:763-70. 2010
  4. pmc Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX)
    Heikki Joensuu
    Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland
    Acta Oncol 53:186-94. 2014
  5. pmc Low vs. high radioiodine activity to ablate the thyroid after thyroidectomy for cancer: a randomized study
    Hanna O Mäenpää
    Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland
    PLoS ONE 3:e1885. 2008
  6. ncbi request reprint Gastrointestinal stromal tumors: risk assessment and adjuvant therapy
    Heikki Joensuu
    Department of Oncology, Helsinki University Central Hospital, Helsinki University, Haartmaninkatu 4, Helsinki FIN 00029, Finland Electronic address
    Hematol Oncol Clin North Am 27:889-904. 2013
  7. doi request reprint Gastrointestinal stromal tumour
    Heikki Joensuu
    Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland
    Lancet 382:973-83. 2013
  8. doi request reprint Adjuvant therapy for high-risk gastrointestinal stromal tumour: considerations for optimal management
    Heikki Joensuu
    Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland
    Drugs 72:1953-63. 2012
  9. ncbi request reprint Adjuvant treatments for triple-negative breast cancers
    H Joensuu
    Department of Oncology, Helsinki University Central Hospital, Haartmaninkatu 4, POB 180, FIN 00029 Helsinki, Finland
    Ann Oncol 23:vi40-5. 2012
  10. pmc Comparison of solution-based exome capture methods for next generation sequencing
    Anna Maija Sulonen
    Institute for Molecular Medicine Finland FIMM, University of Helsinki, Biomedicum Helsinki 2U, Tukholmankatu 8, 00290 Helsinki, Finland
    Genome Biol 12:R94. 2011

Detail Information

Publications152 found, 100 shown here

  1. ncbi request reprint Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer
    Heikki Joensuu
    Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland
    N Engl J Med 354:809-20. 2006
    ..We compared docetaxel with vinorelbine for the adjuvant treatment of early breast cancer. Women with tumors that overexpressed HER2/neu were also assigned to receive concomitant treatment with trastuzumab or no such treatment...
  2. ncbi request reprint Lymphatic vessel density in vocal cord carcinomas assessed with LYVE-1 receptor expression
    Walter J Koskinen
    Department of Virology, Haartman Institute, University of Helsinki, Finland
    Radiother Oncol 77:172-5. 2005
    ..We investigated whether the lymphatic vessel density (LVD) of vocal cord carcinomas differs from that of other head and neck carcinomas...
  3. pmc Expression of KIT receptor tyrosine kinase in endothelial cells of juvenile brain tumors
    Marjut Puputti
    Helsinki Biomedical Graduate School, Helsinki, Finland
    Brain Pathol 20:763-70. 2010
    ..We conclude that KIT is commonly present in endothelial cells of juvenile brain tumors and thus may play a role in angiogenesis in these neoplasms...
  4. pmc Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX)
    Heikki Joensuu
    Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland
    Acta Oncol 53:186-94. 2014
    ..Little information is available about survival outcomes of patients with HER2-positive early breast cancer treated with adjuvant capecitabine-containing chemotherapy with or without trastuzumab...
  5. pmc Low vs. high radioiodine activity to ablate the thyroid after thyroidectomy for cancer: a randomized study
    Hanna O Mäenpää
    Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland
    PLoS ONE 3:e1885. 2008
    ..Radioactive iodine is commonly administered following thyroidectomy for differentiated thyroid carcinoma to ablate the thyroid remnant. The optimal administered activity of radioiodine is unknown...
  6. ncbi request reprint Gastrointestinal stromal tumors: risk assessment and adjuvant therapy
    Heikki Joensuu
    Department of Oncology, Helsinki University Central Hospital, Helsinki University, Haartmaninkatu 4, Helsinki FIN 00029, Finland Electronic address
    Hematol Oncol Clin North Am 27:889-904. 2013
    ..Adjuvant imatinib is usually administered for 3 years at the dose of 400 mg once daily. Early detection of tumors that recur despite adjuvant therapy with longitudinal imaging of the abdomen is likely beneficial...
  7. doi request reprint Gastrointestinal stromal tumour
    Heikki Joensuu
    Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland
    Lancet 382:973-83. 2013
    ..Tyrosine kinase inhibitors substantially improve survival in advanced disease, but secondary drug resistance is common. ..
  8. doi request reprint Adjuvant therapy for high-risk gastrointestinal stromal tumour: considerations for optimal management
    Heikki Joensuu
    Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland
    Drugs 72:1953-63. 2012
    ....
  9. ncbi request reprint Adjuvant treatments for triple-negative breast cancers
    H Joensuu
    Department of Oncology, Helsinki University Central Hospital, Haartmaninkatu 4, POB 180, FIN 00029 Helsinki, Finland
    Ann Oncol 23:vi40-5. 2012
    ..In the absence of data from prospective trials that focus on adjuvant therapy of early TNBC, several regimens, such as a taxane and an anthracycline-containing regimen or classical CMF may be considered reasonable choices...
  10. pmc Comparison of solution-based exome capture methods for next generation sequencing
    Anna Maija Sulonen
    Institute for Molecular Medicine Finland FIMM, University of Helsinki, Biomedicum Helsinki 2U, Tukholmankatu 8, 00290 Helsinki, Finland
    Genome Biol 12:R94. 2011
    ..A control DNA sample was captured with all four capture methods and prepared for Illumina GAII sequencing. Sequence data from additional samples prepared with the same protocols were also used in the comparison...
  11. pmc Long-term prognosis of breast cancer detected by mammography screening or other methods
    Tiina Lehtimäki
    Institute for Molecular Medicine Finland FIMM, University of Helsinki, Biomedicum Helsinki 2U, Tukholmankatu 8, PO Box 20, FI 00014 Helsinki, Finland
    Breast Cancer Res 13:R134. 2011
    ..The purpose of the current study was to compare breast cancer-specific long-term survival of patients whose tumors were detected in mammography screening compared with those whose tumors were detected by other methods...
  12. pmc Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study
    Harri Sihto
    Laboratory of Molecular Oncology, University of Helsinki, Biomedicum Helsinki, Haartmaninkatu 8, 00290, Helsinki, Finland
    Breast Cancer Res 13:R87. 2011
    ..Some molecular subtypes of breast cancer have preferential sites of distant relapse. The protein expression pattern of the primary tumor may influence the first distant metastasis site...
  13. doi request reprint Adjuvant treatment of GIST: patient selection and treatment strategies
    Heikki Joensuu
    Department of Oncology, Helsinki University Central Hospital, Haartmaninkatu 4, POB 180, FIN 00029 Helsinki, Finland
    Nat Rev Clin Oncol 9:351-8. 2012
    ....
  14. ncbi request reprint Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts
    Heikki Joensuu
    Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland
    Lancet Oncol 13:265-74. 2012
    ..We assessed prognostic factors of patients with operable GIST, to compare widely used risk-stratification schemes and to develop a new method for risk estimation...
  15. doi request reprint One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial
    Heikki Joensuu
    Department of Oncology, Helsinki University Central Hospital, Haartmaninkatu 4, PO Box 180, FIN 00029 Helsinki, Finland
    JAMA 307:1265-72. 2012
    ..Adjuvant imatinib administered for 12 months after surgery has improved recurrence-free survival (RFS) of patients with operable gastrointestinal stromal tumor (GIST) compared with placebo...
  16. pmc Development and evaluation of a virtual microscopy application for automated assessment of Ki-67 expression in breast cancer
    Juho Konsti
    FIMM Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland
    BMC Clin Pathol 11:3. 2011
    ..abstract:..
  17. pmc Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study
    H Joensuu
    Department of Oncology, University Central Hospital of Helsinki, Haartmaninkatu 4, Helsinki FIN 00029, Finland
    Br J Cancer 104:1686-90. 2011
    ..We report efficacy and safety results of vatalanib in advanced gastrointestinal stromal tumour (GIST) resistant to imatinib or both imatinib and sunitinib...
  18. doi request reprint Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial
    Heikki Joensuu
    Department of Oncology, Helsinki University Central Hospital, Haartmaninkatu 4, PO Box 180, FIN 00029 Helsinki, Finland
    J Clin Oncol 30:11-8. 2012
    ..It is not known whether integration of capecitabine into an adjuvant regimen that contains a taxane, an anthracycline, and cyclophosphamide improves outcome in early breast cancer...
  19. pmc The management of gastrointestinal stromal tumors: a model for targeted and multidisciplinary therapy of malignancy
    Heikki Joensuu
    Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland
    Annu Rev Med 63:247-58. 2012
    ..Combined or sequential use of tyrosine kinase inhibitors with other agents following tumor molecular subtyping is an attractive next step in the management of GIST...
  20. ncbi request reprint Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial
    Heikki Joensuu
    Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland
    Lancet Oncol 10:1145-51. 2009
    ..We aimed to investigate whether integration of capecitabine into such a regimen enhances outcome...
  21. ncbi request reprint Boron neutron capture therapy of brain tumors: clinical trials at the finnish facility using boronophenylalanine
    Heikki Joensuu
    Department of Oncology, University of Helsinki, Finland
    J Neurooncol 62:123-34. 2003
    ..Efficacy comparisons with conventional photon radiation are difficult due to patient selection and confounding factors such as other treatments given, but the results support continuation of clinical research on BPA-based BNCT...
  22. ncbi request reprint Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study
    Heikki Joensuu
    Department of Oncology, Helsinki University Central Hospital, Haartmaninkatu 4, PO Box 180, FIN 00029 Helsinki, Finland
    Clin Cancer Res 9:923-30. 2003
    ..To assess the relative importance of 10 prognostic factors in pT1N0M0 breast cancer (< or =2 cm in diameter, node negative)...
  23. ncbi request reprint Treatment of inoperable gastrointestinal stromal tumor (GIST) with Imatinib (Glivec, Gleevec)
    Heikki Joensuu
    Department of Oncology, Helsinki University Central Hospital, Finland
    Med Klin (Munich) 97:28-30. 2002
    ..Imatinib (STI571 or Glivec, Novartis) is a new type of tyrosine kinase inhibitor that selectively inhibits various tyrosine kinases including ABL, BCR-ABL, KIT and PDGF receptors...
  24. ncbi request reprint Soluble syndecan-1 and serum basic fibroblast growth factor are new prognostic factors in lung cancer
    Heikki Joensuu
    Department of Oncology, Helsinki University Central Hospital, Haartmaninkatu 4, PO Box 180, FIN 00029 Helsinki
    Cancer Res 62:5210-7. 2002
    ..0-2.7) had independent influence on survival in a multivariate survival analysis in non-small cell lung cancer. We conclude that high serum syndecan-1 and bFGF levels at diagnosis are associated with poor outcome in lung cancer...
  25. doi request reprint Very high quantitative tumor HER2 content and outcome in early breast cancer
    H Joensuu
    Department of Oncology, Helsinki University Central Hospital and University of Helsinki, Helsinki, Finland
    Ann Oncol 22:2007-13. 2011
    ..It is unknown how a very high tumor total HER2 (human epidermal growth factor receptor-2) content (H2T) influences outcome in early breast cancer treated with adjuvant trastuzumab plus chemotherapy...
  26. ncbi request reprint Management of malignant gastrointestinal stromal tumours
    Heikki Joensuu
    Department of Oncology and Radiotherapy, Helsinki University Central Hospital, Helsinki, Finland
    Lancet Oncol 3:655-64. 2002
    ..Responses have been durable, and most patients tolerate the drug well at clinically effective doses. Imatinib mesylate is the first effective systemic therapy for advanced GIST...
  27. doi request reprint Practical management of tyrosine kinase inhibitor-associated side effects in GIST
    Heikki Joensuu
    Department of Oncology, Helsinki University Central Hospital and Helsinki University, Helsinki, Finland
    Cancer Treat Rev 37:75-88. 2011
    ..Management of many TKI-related adverse effects require further evaluation in prospective clinical trials...
  28. ncbi request reprint [Tyrosine kinase inhibitor as a targeted therapy for GIST tumors]
    Heikki Joensuu
    HYKS n syöpätautien klinikka PL 180, 00029 HUS
    Duodecim 118:2305-12. 2002
  29. ncbi request reprint Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial
    Heikki Joensuu
    Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland
    J Clin Oncol 27:5685-92. 2009
    ..Efficacy and long-term safety of a short course of adjuvant trastuzumab administered concomitantly with chemotherapy for human epidermal growth factor receptor 2 (HER2) -positive cancer are unknown...
  30. pmc Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a randomised trial
    H Joensuu
    Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland
    Ann Oncol 21:968-73. 2010
    ..Alternating administration of docetaxel and gemcitabine might result in improved time-to-treatment failure (TTF) and fewer adverse events compared with single-agent docetaxel as treatment of advanced breast cancer...
  31. ncbi request reprint Aromatase inhibitors in the treatment of early and advanced breast cancer
    Heikki Joensuu
    Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland
    Acta Oncol 44:23-31. 2005
    ..Third generation aromatase inhibitors may be considered as the first line therapy of hormone-receptor-positive advanced breast cancer in postmenopausal women, and they may also be used for preoperative therapy of breast cancer...
  32. ncbi request reprint Second line therapies for the treatment of gastrointestinal stromal tumor
    Heikki Joensuu
    Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland
    Curr Opin Oncol 19:353-8. 2007
    ..Most gastrointestinal stromal tumors eventually acquire resistance to imatinib mesylate. This review focuses on recent progress on management of patients whose disease progresses on the standard dose of imatinib...
  33. ncbi request reprint Cardiac toxicity of sunitinib
    Heikki Joensuu
    Department of Oncology, Helsinki University Central Hospital, Helsinki, FIN 00029, Finland
    Lancet 370:1978-80. 2007
  34. ncbi request reprint Risk for distant recurrence of breast cancer detected by mammography screening or other methods
    Heikki Joensuu
    Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland
    JAMA 292:1064-73. 2004
    ..In such estimations, tumors detected by mammography screening are considered to be associated with a similar risk of recurrence as tumors of similar size found by other methods...
  35. ncbi request reprint [Aromatase inhibitors in breast cancer therapy]
    Heikki Joensuu
    HYKS n syöpätautien klinikka, HUS
    Duodecim 120:1301-4. 2004
  36. doi request reprint Systemic chemotherapy for cancer: from weapon to treatment
    Heikki Joensuu
    Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland
    Lancet Oncol 9:304. 2008
  37. ncbi request reprint Gastrointestinal stromal tumors--a review
    H Joensuu
    Dept of Oncology and Radiotherapy, Helsinki University Central Hospital, Helsinki, Finland
    Acta Orthop Scand Suppl 75:62-71. 2004
    ..In contrast, responses to conventional chemotherapy are infrequent (generally less than 10%), but combination therapies with imatinib have not been explored. Research on adjuvant imatinib and novel targeted therapies is ongoing...
  38. ncbi request reprint Amplification of genes encoding KIT, PDGFRalpha and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme
    Heikki Joensuu
    Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland
    J Pathol 207:224-31. 2005
    ..We conclude that KIT, PDGFRA and VEGFR2 are commonly amplified in primary glioblastoma and that they may also be amplified in secondary glioblastoma. Amplified kinases may be potential targets for tyrosine kinase inhibitor therapy...
  39. ncbi request reprint Serum lipid levels during and after adjuvant toremifene or tamoxifen therapy for breast cancer
    H Joensuu
    Department of Oncology, Helsinki University Central Hospital, Finland
    Breast Cancer Res Treat 63:225-34. 2000
    ..In conclusion, we found no major differences between 40 mg toremifene and 20 mg of tamoxifen in their effect on the serum lipid levels, which return to the pretreatment levels within 6 months after cessation of therapy...
  40. ncbi request reprint Risk stratification of patients diagnosed with gastrointestinal stromal tumor
    Heikki Joensuu
    Department of Oncology, Helsinki University Central Hospital, FIN 00029 Helsinki, Finland
    Hum Pathol 39:1411-9. 2008
    ..The proposed system, if validated, may be useful in identifying which patients might potentially benefit from adjuvant therapy...
  41. ncbi request reprint Sunitinib for imatinib-resistant GIST
    Heikki Joensuu
    Department of Oncology, Helsinki University Central Hospital, Haartmaninkatu 4, Finland
    Lancet 368:1303-4. 2006
  42. ncbi request reprint Postoperative PINP in serum reflects metastatic potential and poor survival in node-positive breast cancer
    A Jukkola
    Department of Oncology, University of Oulu, Finland
    Anticancer Res 21:2873-6. 2001
    ..also a factor for poorer survivaL Tumor size, malignancy grade and progesterone receptors were shown in multivariate analysis to be predictors of recurrence and tumor size and PINP and progesterone receptors to be predictors of survivaL..
  43. ncbi request reprint Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate
    H Joensuu
    Department of Oncology, University Central Hospital of Helsinki, Helsinki, Finland
    Ann Oncol 19:173-7. 2008
    ..This is the first study of PTK/ZK in this population...
  44. pmc Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors
    P Salven
    Department of Oncology, Helsinki University Central Hospital, Finland
    Am J Pathol 153:103-8. 1998
    ..Furthermore, VEGF-C and VEGF-B can, similarly to VEGF, be involved in tumor angiogenesis...
  45. ncbi request reprint Vascular endothelial growth factor in squamous cell head and neck carcinoma: expression and prognostic significance
    P Salven
    Department of Oncology, Helsinki University Central Hospital, Finland
    Mod Pathol 10:1128-33. 1997
    ..In squamous cell head and neck cancer, carcinoma cell VEGF expression is not a prognostic marker...
  46. pmc Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF
    P Poikonen
    Department of Oncology, Helsinki University Central Hospital, Finland
    Br J Cancer 80:1763-6. 1999
    ..A low leucocyte nadir during the adjuvant CMF chemotherapy is associated with favourable DDFS and it may be a useful biological marker for chemotherapy efficacy...
  47. ncbi request reprint A phase I study of raltitrexed (Tomudex) combined with carmofur in metastatic colorectal cancer
    P Osterlund
    Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland
    Oncology 61:113-9. 2001
    ..The aim of the study was to define the maximum tolerated dose (MTD) of the combination of raltitrexed plus carmofur, and to evaluate the tolerability and efficacy of this combination in metastatic colorectal cancer...
  48. ncbi request reprint Effect of obesity on the leukocyte nadir in women treated with adjuvant cyclophosphamide, methotrexate, and fluorouracil dosed according to body surface area
    P Poikonen
    Department of Oncology, Helsinki University Central Hospital, Finland
    Acta Oncol 40:67-71. 2001
    ..Therefore, the drug doses should not be reduced because of obesity, and even when obese patients are treated according to the scheduled doses they may remain slightly underdosed...
  49. ncbi request reprint High syndecan-1 expression is associated with favourable outcome in squamous cell lung carcinoma treated with radical surgery
    A Anttonen
    Department of Oncology, Helsinki University Central Hospital, FIN-00029 HUS, Helsinki, Finland
    Lung Cancer 32:297-305. 2001
    ..We conclude that syndecan-1 expression decreases in parallel with histological dedifferentiation in squamous cell carcinoma of the lung, and that low syndecan-1 expression is associated with unfavourable outcome...
  50. ncbi request reprint Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor
    H Joensuu
    Department of Oncology, Helsinki University Central Hospital, Finland
    N Engl J Med 344:1052-6. 2001
  51. ncbi request reprint Endothelial cell KIT expression in human tumours
    H Sihto
    Laboratory of Molecular Oncology, Biomedicum Helsinki, Department of Pathology, Helsinki University Central Hospital, Finland
    J Pathol 211:481-8. 2007
    ..Endothelial cell and tumour cell expression of activated KIT might explain in part the responsiveness of glioblastomas to the combination of imatinib (an inhibitor of KIT) and hydroxyurea...
  52. pmc Subclinical cardiotoxicity following adjuvant dose-escalated FEC, high-dose chemotherapy, or CMF in breast cancer
    T Erselcan
    Department of Oncology, Helsinki University Central Hospital, Finland
    Br J Cancer 82:777-81. 2000
    ..001). We conclude that subclinical cardiac damage caused by three cycles of conventional-dose FEC followed by one cycle of high-dose CTCb chemotherapy is small as compared with the damage caused by dose-escalated FEC...
  53. pmc Syndecan-1 expression has prognostic significance in head and neck carcinoma
    A Anttonen
    Department of Oncology, Helsinki University Central Hospital, Finland
    Br J Cancer 79:558-64. 1999
    ..We conclude that syndecan-1 is a novel prognostic factor in SCC of the head and neck treated with surgery and post-operative radiotherapy...
  54. ncbi request reprint Omission of histologic grading from clinical decision making may result in overuse of adjuvant therapies in breast cancer: results from a nationwide study
    J Lundin
    Department of Oncology, University of Helsinki, Helsinki, Finland
    J Clin Oncol 19:28-36. 2001
    ..To investigate the influence of routinely performed histologic grading on breast cancer outcome prediction and patient selection for adjuvant therapy...
  55. pmc Comparison of benign and malignant follicular thyroid tumours by comparative genomic hybridization
    S Hemmer
    Department of Oncology, Helsinki University Central Hospital, Finland
    Br J Cancer 78:1012-7. 1998
    ..These changes are strikingly different from those found in follicular carcinomas consisting of few losses and frequent gains, especially those of chromosome 7. A loss of chromosome 22 is common in widely invasive follicular carcinoma...
  56. pmc Bcl-2 protein expression and long-term survival in breast cancer
    H Joensuu
    Department of Oncology, Turku University Central Hospital, Finland
    Am J Pathol 145:1191-8. 1994
    ..We conclude that Bcl-2 protein is frequently expressed in breast cancer, and its expression is associated with favorable clinicopathological features...
  57. ncbi request reprint Treatment results of nasopharyngeal cancer--a nationwide survey from Finland
    M Kajanti
    Department of Oncology, Helsinki University Central Hospital, Finland
    Acta Oncol 35:697-702. 1996
    ....
  58. ncbi request reprint Intensified adjuvant cyclophosphamide, methotrexate and 5-fluorouracil therapy: a dose-finding study for ambulatory patients with breast cancer
    P Hietanen
    Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland
    Oncology 56:103-9. 1999
    ..We conclude that intravenous CMF with a cyclophosphamide dose of 1,500 mg/m2 given at 3-week intervals with the selective use of prophylactic G-CSF is feasible as adjuvant treatment for patients with breast cancer...
  59. ncbi request reprint Serum tumour markers CA 15-3, TPA, TPS, hCGbeta and TATI in the monitoring of chemotherapy response in metastatic breast cancer
    J Sjöstrom
    Department of Oncology, Helsinki University Hospital, Finland
    Scand J Clin Lab Invest 61:431-41. 2001
    ..In conclusion, changes in CA 15-3 or TPS levels usually correlate with clinical response, but owing to distinct discordances, they should not be used as sole indicators of response to chemotherapy in advanced breast cancer...
  60. ncbi request reprint Serum VEGF levels in women with a benign breast tumor or breast cancer
    P Salven
    Department of Oncology, Helsinki University, Central Hospital, Finland
    Breast Cancer Res Treat 53:161-6. 1999
    ..021). The results indicate that dissemination of breast cancer may be accompanied by an elevation of circulating VEGF and that primary ductal cancers are associated with higher S-VEGF levels than lobular cancers or benign breast lesions...
  61. ncbi request reprint High pretreatment serum concentration of basic fibroblast growth factor is a predictor of poor prognosis in small cell lung cancer
    Tarja Ruotsalainen
    Department of Internal Medicine, Helsinki University Central Hospital, FIN 00290 Helsinki, Finland
    Cancer Epidemiol Biomarkers Prev 11:1492-5. 2002
    ..0057). We conclude that a high S-bFGF at diagnosis is associated with poor outcome in small cell lung cancer, possibly reflecting active angiogenesis and rapid tumor growth, and may complement prognostic information obtained by staging...
  62. pmc Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study
    P Osterlund
    Department of Oncology, Helsinki University Central Hospital, PO Box 180, 00029 HUS Helsinki, Finland
    Br J Cancer 97:1028-34. 2007
    ..We conclude that Lactobacillus GG supplementation is well tolerated and may reduce the frequency of severe diarrhoea and abdominal discomfort related to 5-FU-based chemotherapy...
  63. ncbi request reprint A high pretreatment serum basic fibroblast growth factor concentration is an independent predictor of poor prognosis in non-Hodgkin's lymphoma
    P Salven
    Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland
    Blood 94:3334-9. 1999
    ....
  64. ncbi request reprint Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor
    P Salven
    Department of Oncology, Helsinki University Central Hospital, Finland
    Clin Cancer Res 5:487-91. 1999
    ..VEGF in serum samples originates from blood cells, and the use of VEGF of whole blood or of isolated blood cells may improve the clinical value of VEGF measurements...
  65. ncbi request reprint Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy
    A Hemminki
    Department of Medical Genetics, Haartman Institute, University of Helsinki, Helsinki, Finland
    Gastroenterology 119:921-8. 2000
    ..We investigated the safety of adjuvant 5-FU-based chemotherapy for MSI(+) CRC and compared the prognosis of MSI(+) and MSI(-) CRC patients receiving adjuvant therapy...
  66. doi request reprint Tumour microvessel endothelial cell KIT and stem cell factor expression in human solid tumours
    Harri Sihto
    Laboratory of Molecular Oncology, Biomedicum Helsinki, Helsinki, Finland
    Histopathology 55:544-53. 2009
    ..To assess KIT receptor tyrosine kinase and stem cell factor (SCF, KIT ligand) expression in tumour microvessel endothelial cells...
  67. ncbi request reprint KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors
    Harri Sihto
    Department of Oncology, Helsinki University Central Hospital, Haartmaninkatu 4, PO Box 180, FIN 00029 Helsinki, Finland
    J Clin Oncol 23:49-57. 2005
    ..The frequency of activating KIT and PDGFRA gene mutations in most other histologic types of human cancer is not known...
  68. ncbi request reprint Stage I non-Hodgkin's lymphoma treated with doxorubicin-containing chemotherapy with or without radiotherapy
    K Villikka
    Department of Oncology, Helsinki University Central Hospital, Finland
    Acta Oncol 36:619-24. 1997
    ..18). We conclude that stages I and IE intermediate-grade or immunoblastic non-Hodgkin's Hodgkin's lymphoma is highly curable if treated with short doxorubicin-containing chemotherapy and involved field radiotherapy...
  69. pmc Endothelial Tie growth factor receptor provides antigenic marker for assessment of breast cancer angiogenesis
    P Salven
    Department of Oncology, Helsinki University Central Hospital, Finland
    Br J Cancer 74:69-72. 1996
    ....
  70. pmc Expression and prognostic value of transcription factor PROX1 in colorectal cancer
    M Skog
    Department of Oncology, Helsinki University Central Hospital, Helsinki FIN 00029 HUS, Finland
    Br J Cancer 105:1346-51. 2011
    ..It acts as a regulator of progression from a benign to a highly dysplastic phenotype in colorectal tumours. However, the clinical significance of PROX1 expression is not known...
  71. pmc Lymphocyte homing receptor (CD44) expression is associated with poor prognosis in gastrointestinal lymphoma
    H Joensuu
    Department of Oncology and Radiotherapy, Turku University Central Hospital, Finland
    Br J Cancer 68:428-32. 1993
    ..02). We conclude that lack of lymphocyte homing receptor expression is common in gastrointestinal lymphoma, and that CD44 expression is associated with unfavourable prognosis...
  72. ncbi request reprint Interferon alpha-2a therapy in 18 hemangioblastomas
    M Niemela
    Department of Neurosurgery, Helsinki University Central Hospital, Finland
    Clin Cancer Res 7:510-6. 2001
    ..The systemic response was also monitored by measurement of serum levels of vascular endothelial growth factor and erythropoietin, which remained essentially unchanged during the treatment. No serious side effects were recorded...
  73. ncbi request reprint Effect of treatment of larynx and hypopharynx carcinomas on serum syndecan-1 concentrations
    A Anttonen
    Department of Oncology, Helsinki University Central Hospital, P O Box 180, 00029 Helsinki, Finland
    J Cancer Res Clin Oncol 132:451-7. 2006
    ..We studied S-syndecan-1 levels longitudinally in a series of patients diagnosed with locoregional squamous cell larynx or hypopharynx carcinoma (n=44) and who we treated with surgery and/or radiation therapy...
  74. ncbi request reprint A phase I study of an all-oral combination of vinorelbine/capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and/or taxanes
    Pirkko Liisa Kellokumpu-Lehtinen
    Department of Oncology, Tampere University Hospital, Finland
    Clin Breast Cancer 7:401-5. 2006
    ..An all-oral regimen minimizes inconvenience for the patient and saves medical resources...
  75. ncbi request reprint Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib
    Petri Bono
    Department of Oncology, University Central Hospital of Helsinki, Helsinki, Finland
    Blood 103:2929-35. 2004
    ..1-259-fold). A high serum SCF/KIT ratio may increase SCF-induced cell signaling with prolonged imatinib treatment, at the time when imatinib treatment is withdrawn, and in patients whose GIST has wild-type receptors...
  76. ncbi request reprint Surgical treatment in Paget's disease of the breast
    Elina Siponen
    Helsinki University Central Hospital, Finland
    Am J Surg 200:241-6. 2010
    ..The aim of this study was to evaluate the outcomes of surgical treatment of Paget's disease of the breast, with special emphasis on magnetic resonance imaging (MRI) and sentinel node biopsy (SNB)...
  77. doi request reprint Molecular subtypes of breast cancers detected in mammography screening and outside of screening
    Harri Sihto
    Laboratory of Molecular Oncology, Biomedicum, Helsinki University Central Hospital, Helsinki, Finland
    Clin Cancer Res 14:4103-10. 2008
    ..The frequency and significance of gene expression profile-derived molecular subtypes of breast cancers found in mammography screening are unknown...
  78. doi request reprint Expression of CD11b/CD18 adhesion molecules on circulating phagocytes-a novel aid to diagnose infection in patients with cancer
    R Kallio
    Department of Oncology and Radiotherapy, Oulu University Hospital, Box 22, 90029, Oulu, Finland
    Support Care Cancer 16:1389-96. 2008
    ..No blood marker available to date is useful for distinguishing infection-related from neoplasm-related fever. We evaluated the expression of the peripheral blood phagocyte CD11b/CD18 adhesion molecule complex for this purpose...
  79. ncbi request reprint Clinical significance of circulating CD44 in non-Hodgkin's lymphoma
    R Ristamaki
    National Public Health Institute, Department of Oncology, University of Turku, Finland
    Int J Cancer 79:221-5. 1998
    ..Our previous and present studies taken together suggest that measurement of s-CD44 is a valuable tool to monitor treatment response in lymphoma patients. However, it may not be an improved prognostic marker...
  80. pmc Genetic alterations and protein expression of KIT and PDGFRA in serous ovarian carcinoma
    H Lassus
    Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Haartmaninkatu 2, Helsinki 00290, Finland
    Br J Cancer 91:2048-55. 2004
    ..In conclusion, no mutations of KIT or PDGFRA were found, but a subset of serous ovarian carcinoma showed overexpression of the proteins, which was associated with aggressive tumour characteristics...
  81. ncbi request reprint Generalisability of survival estimates for patients with breast cancer--a comparison across two population-based series
    Johan Lundin
    Department of Oncology, Helsinki University Central Hospital, Haartmaninkatu 4, P O Box 180, FIN 00029 Helsinki, Finland
    Eur J Cancer 42:3228-35. 2006
    ..The results suggest that quantitative survival estimates based on frequently used prognostic factors and prognostication schemes are generalisable and transportable between large, unselected cohorts of breast cancer patients...
  82. doi request reprint Sentinel node biopsy in breast cancer patients with large or multifocal tumors
    Tuomo J Meretoja
    Department of Gastrointestinal and General Surgery, Breast Surgery Unit, Helsinki University Central Hospital, Helsinki, Finland
    Ann Surg Oncol 16:1148-55. 2009
    ..The aim of this study was to analyze the risk factors for isolated AR after negative SNB with special interest in large or multifocal tumors...
  83. ncbi request reprint Clinical factors associated with Merkel cell polyomavirus infection in Merkel cell carcinoma
    Harri Sihto
    Laboratory of Molecular Oncology, Biomedicum, Helsinki, Finland
    J Natl Cancer Inst 101:938-45. 2009
    ..Merkel cell carcinoma is a rare malignancy of the skin. Integration of Merkel cell polyomavirus (MCPyV) DNA to the tumor genome is frequent in these cancers. The clinical consequences of MCPyV infection are unknown...
  84. ncbi request reprint Ki-67 expression level, histological subtype, and the International Prognostic Index as outcome predictors in mantle cell lymphoma
    Riikka Räty
    Department of Medicine, Helsinki University Central Hospital, Finland
    Eur J Haematol 69:11-20. 2002
    ..We assessed the significance of the cell proliferation rate as an outcome predictor with the five components of the International Prognostic Index (IPI) and the histological subtypes of MCL...
  85. ncbi request reprint Association of cyclooxygenase-2 and matrix metalloproteinase-2 expression in human breast cancer
    Anna Sivula
    Department of Pathology, Helsinki University Central Hospital, Helsinki, Finland
    Breast Cancer Res Treat 89:215-20. 2005
    ..021, respectively). Taken together, our results indicate that expression of COX-2 protein is associated with expression of MMP-2 protein in human breast cancer and that both COX-2 and MMP-2 are markers of poor prognosis in breast cancer...
  86. doi request reprint Safety of sentinel node biopsy in breast cancer patients who receive a second radioisotope injection after visualization failure in lymphoscintigraphy
    Tuomo J Meretoja
    Breast Surgery Unit, Helsinki University Central Hospital, Helsinki, Finland
    J Surg Oncol 102:649-55. 2010
    ..We investigated the axillary recurrence rate after tumor-negative SNB in breast cancer patients who received a second tracer injection after axillary visualization failure in lymphoscintigraphy...
  87. ncbi request reprint PPP2R1B gene in chronic lymphocytic leukemias and mantle cell lymphomas
    Y Zhu
    Department of Medical Genetics, Haartman Institute; Helsinki University Central Hospital, University of Helsinki, Finland
    Leuk Lymphoma 41:177-83. 2001
    ..To exclude the possibility of large genomic deletions we performed Southern blotting analysis. One MCL sample showed abnormal bands. Our results do not suggest that the PPP2R1B gene has a major pathogenic role in CLL and MCL...
  88. ncbi request reprint Causes and consequences of BCL2 overexpression in diffuse large B-cell lymphoma
    S Rantanen
    Department of Medical Genetics, Haartman Institute and Helsinki University Central Hospital, University of Helsinki, Finland
    Leuk Lymphoma 42:1089-98. 2001
    ..Bcl-2 protein overexpression as determined by IHC is associated with poor response to chemotherapy and poor survival...
  89. ncbi request reprint Risk factors for screen-detected breast cancer. A case-control study
    H Joensuu
    Department of Oncology and Radiotherapy, Turku University Central Hospital, Finland
    Acta Oncol 31:729-32. 1992
    ....
  90. ncbi request reprint Vinorelbine, methotrexate and fluorouracil (VMF) as first-line therapy in metastatic breast cancer: a randomized phase II trial
    I Elomaa
    Cancer Center, University Hospital of Helsinki, Finland
    Ann Oncol 14:699-703. 2003
    ..The purpose of this study was to determine the best tolerated and efficacious dose of vinorelbine given once or twice in 3-week cycles in combination with methotrexate and fluorouracil (VMF)...
  91. ncbi request reprint Phase I trial on sms-D70 somatostatin analogue in advanced prostate and renal cell cancer
    T K Joensuu
    Department of Oncology, Helsinki University Central Hospital, Haartmaninkatu 4, Helsinki, Finland
    Ann N Y Acad Sci 1028:361-74. 2004
    ..In conclusion, sms-D70 was well tolerated in the treatment of metastatic prostate and renal cell cancer, but no responses were found in these heavily treated patients...
  92. pmc Chronic lymphocytic leukaemia patients have a high risk of Merkel-cell polyomavirus DNA-positive Merkel-cell carcinoma
    V Koljonen
    Department of Plastic Surgery, Helsinki University Central Hospital, Helsinki, Finland
    Br J Cancer 101:1444-7. 2009
    ..Immunosuppression and Merkel-cell polyomavirus (MCPyV) infection may have a role in the pathogenesis of Merkel-cell carcinoma (MCC), a rare neuroendocrine carcinoma of the skin...
  93. ncbi request reprint Financial compensation for radiotherapy-related adverse events in a judicial system where proof of medical negligence is not required
    P Nyandoto
    Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland
    Int J Radiat Oncol Biol Phys 51:209-12. 2001
    ....
  94. ncbi request reprint Skin toxicity as a risk factor for major infections in breast cancer patients treated with docetaxel
    Paula Poikonen
    Department of Oncology, Helsinki University Central Hospital, Finland
    Acta Oncol 43:190-5. 2004
    ....
  95. ncbi request reprint Comparison of granulocyte-macrophage colony-stimulating factor and sucralfate mouthwashes in the prevention of radiation-induced mucositis: a double-blind prospective randomized phase III study
    Kauko Saarilahti
    Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland
    Int J Radiat Oncol Biol Phys 54:479-85. 2002
    ..To compare granulocyte-macrophage colony-stimulating factor (GM-CSF) mouthwashes with sucralfate mouthwashes in the prevention of radiation-induced mucositis...
  96. ncbi request reprint Lactose intolerance associated with adjuvant 5-fluorouracil-based chemotherapy for colorectal cancer
    Pia Osterlund
    Department of Oncology, Helsinki University Central Hospital, Finland
    Clin Gastroenterol Hepatol 2:696-703. 2004
    ..Bowel mucosal injury associated with 5-fluorouracil (5-FU) treatment might result in secondary lactose intolerance. The frequency and clinical significance of 5-FU-related hypolactasia are unknown...
  97. doi request reprint The outcome of sentinel node biopsy in breast cancer patients with preoperative surgical biopsy
    Marjut H K Leidenius
    Breast Surgery Unit, Helsinki University Central Hospital, P O Box 140, 00029 HUS, Helsinki, Finland
    J Surg Oncol 99:420-3. 2009
    ..The aim of the study was to evaluate the outcome of sentinel node biopsy (SNB), especially the medium term axillary recurrence rate after negative SNB in patients with preoperative surgical biopsy (SB)...
  98. ncbi request reprint Interferon alfa-2b three times daily and thalidomide in the treatment of metastatic renal cell carcinoma
    Micaela Hernberg
    Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland
    J Clin Oncol 21:3770-6. 2003
    ..To evaluate this potential, we treated patients with metastatic renal cell carcinoma (RCC) with frequently dosed IFN and thalidomide...
  99. ncbi request reprint Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer
    Ari Ristimaki
    Department of Pathology, Molecular and Cancer Research Program, Helsinki University Central Hospital, P O Box 63 Haartmaninkatu 8, FIN 00014 Helsinki, Finland
    Cancer Res 62:632-5. 2002
    ..The present findings support efforts to initiate clinical trials on the efficacy of Cox-2 inhibitors in adjuvant treatment of breast cancer...
  100. ncbi request reprint Hepatocyte growth factor receptor, matrix metalloproteinase-11, tissue inhibitor of metalloproteinase-1, and fibronectin are up-regulated in papillary thyroid carcinoma: a cDNA and tissue microarray study
    Veli Matti Wasenius
    Department of Oncology, Helsinki University Central Hospital, FIN 00029 Helsinki, Finland
    Clin Cancer Res 9:68-75. 2003
    ....